Dr. Teresa Lever: Shaping Aerodigestive Health

​

Dr. Teresa Lever is an internationally recognized expert in swallowing and aerodigestive disorders, with significant contributions to research, clinical innovation, and commercialization in this field. Her expertise is most prominent in the intersection of digestive and respiratory health, especially as it relates to neurological disease. As a clinician-scientist and Professor of Otolaryngology at the University of Missouri School of Medicine, she has established herself as a leading voice in advancing our understanding and treatment of aerodigestive health disorders.

​

With over 20 years of clinical experience in speech-language pathology, Dr. Lever has dedicated her career to improving patient outcomes in adult-onset neurological disorders such as ALS, Parkinson’s disease, and stroke. Her research spans basic science, veterinary medicine, and clinical studies, embracing a "One Health" approach that bridges human and animal health. Dr. Lever's scientific impact extends worldwide through her publications and collaborations.

​

Key Achievements

• Innovative Technologies: Dr. Lever has developed and patented several tools and methods to objectively quantify aerodigestive tract functions across species. These innovations are being used in numerous animal and human studies to enhance diagnostic accuracy and treatment efficacy.                                                                                                                                                                                                         

• Interdisciplinary Research: Funded by grants from the National Institutes of Health (NIH) and National Science Foundation (NSF), Dr. Lever collaborates with researchers from various fields, including respiratory physiology, engineering, neurology, otolaryngology, and radiology, to address the complex challenges of dysphagia.                                                                                                                                                                                                                         

• Translational Impact: Her research focuses on translating biomedical innovations into clinician-friendly diagnostic and treatment tools. This includes adapting treatments proven effective in animal models for use in human clinical trials, aiming to improve the quality of life for individuals with dysphagia.                                                                                                                                                                                                                               

•                                                                                                                                                ​

Legacy and Impact

As a respected authority in her field, Dr. Lever's work has laid the foundation for Aerodigestive Health Corporation (AHC), a company dedicated to advancing aerodigestive health through innovative technologies. Her vision and contributions continue to inspire and guide AHC's mission to enhance diagnostic accuracy, treatment efficacy, and patient outcomes for humans and animals.